Akums Drugs & Pharmaceuticals Ltd (AKUMS) is currently trading at 735.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Akums Drugs & Pharmaceuticals is an India‑based integrated CDMO and pharmaceutical group providing contract development and manufacturing services, active pharmaceutical ingredients, domestic and international branded formulations, and cosmeceuticals, operating multiple manufacturing sites and R&D centres focused on regulated‑market filings and formulation development. Q1 FY27 delivered revenue of INR1,167 crores, up 13.9% year‑on‑year, with operating EBITDA of INR175 crores growing 35.4% and PAT of INR101 crores up 56.1%, reflecting strong CDMO momentum, higher utilization and a rebound in API prices that materially improved margins across the business. CDMO remains the dominant engine with INR964 crores of revenue in Q1 FY27, up 18.6% year‑on‑year; management reports high‑teens volume growth and expects the segment to sustain strong volumes and maintain corporate EBITDA margins in the targeted 14–15% annual range. Akums entered cosmetics manufacturing with the acquisition of Oriflame India’s manufacturing assets and continues to pursue selective inorganic opportunities, supported by a net cash position of approximately INR1,616 crores and explicit appetite for value‑accretive M&A to broaden capabilities and drive margin expansion. Management highlighted a clear roadmap to make the API segment EBITDA‑positive by the end of FY27, while international initiatives including Zambia supplies and planned European operations are expected to provide higher‑margin revenue and long‑term structural benefits.

Over the past 52 weeks, Akums Drugs & Pharmaceuticals Ltd has traded between a low of ₹410.10 and a high of ₹839.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Akums Drugs & Pharmaceuticals Ltd has a market capitalization of approximately 11,664.47. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Akums Drugs & Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 39.85 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 11,664.47 Cr, Akums Drugs & Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Akums Drugs & Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Akums Drugs & Pharmaceuticals Ltd is 39.85. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The results-related board meeting is scheduled for August 08, 2026.

Akums Drugs and Pharmaceuticals launched dapagliflozin plus pioglitazone tablets, a combination therapy for the management of type 2 diabetes.

A total dividend of ₹3.00 per share, comprising a ₹1.00 final dividend and a ₹2.00 special dividend for the year ended March 31, 2026.